
Carisma Therapeutics Concentrates on Promising CT-0525, Restructures to Manage Finances amid 2023 Losses
PHILADELPHIA, PA — Carisma Therapeutics Inc. (NASDAQ: CARM) recently disclosed its financial results for the fourth quarter and the full year concluding on December 31, 2023, outlining a plan to …
Carisma Therapeutics Concentrates on Promising CT-0525, Restructures to Manage Finances amid 2023 Losses Read More